Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shugan Jieyu Capsules for Post-Stroke Depression – Neurobiological Mechanisms
ChiCTR2600122495Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Apr 2026
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Shugan Jieyu in major depressive disorder (MDD) (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Change in HAMD-17 score from baseline at 12 weeks, Changes in mRS score and 8 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Shugan Jieyu
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600122495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122495.